TrippBio, Inc. Press Releases

• Published on January 22, 2024 - 11:04 GMT

  

  TrippBio Publishes Data Comparing PanCytoVir™ versus Oseltamivir Against H5N1 and H7N9 Pandemic Influenza

  PanCytoVir™ therapy provided 100% protection against lethal H5N1 infection, complete elimination of H5N1 from the lungs, and a greater reduction in inflammation JACKSONVILLE, FL, USA, January 22, 2024 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. (TrippBio), a …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on December 4, 2023 - 11:04 GMT

  

  TrippBio Publishes Data Comparing the in vitro and in vivo Activity of PanCytoVir™ versus Oseltamivir

  • PanCytoVir™ demonstrates greater potency against strains of influenza A and B and variants known to be resistant to oseltamivir JACKSONVILL, FL, USA, December 4, 2023 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. (TrippBio), a clinical development-stage …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on November 29, 2023 - 12:05 GMT

  

  TrippBio Presents at the World Vaccine Congress West Coast 2023 Meeting

  PanCytoVir™ showed 100% protection against lethal H5N1 infection in mice, the complete elimination of infectious virus and a greater reduction of inflammation JACKSONVILLE, FL, UNITED STATES, November 29, 2023 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. ( …

  Distribution channels: Agriculture, Farming & Forestry Industry, Emergency Services ...
• Published on September 21, 2023 - 11:05 GMT

  

  TrippBio Announces Clearance of Investigational New Drug Application for PanCytoVir™ Treatment of Influenza

  • First study will evaluate the pharmacokinetics of a novel oral PanCytoVir™ suspension JACKSONVILLE, FL, UNITED STATES, September 21, 2023 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. (TrippBio), a clinical development-stage biopharmaceutical company …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on August 22, 2023 - 11:15 GMT

  

  TrippBio Submits an Investigational New Drug Application to the U.S. FDA for PanCytoVir™ Treatment of Influenza

  First study will evaluate the pharmacokinetics of a novel oral PanCytoVir suspension JACKSONVILLE, FLORIDA, UNITED STATES, August 22, 2023 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. (TrippBio), a clinical development-stage biopharmaceutical company developing …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on July 6, 2023 - 16:56 GMT

  

  TrippBio Announces Results of a Phase 2 Study of PanCytoVir™ in Patients with Mild-to-Moderate COVID-19

  • Potent antiviral efficacy observed • Treatment with PanCytoVir™ resulted in a significant increase in the proportion of patients completely free of symptoms JACKSONVILLE, FL, USA, July 6, 2023 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. (TrippBio), a …

  Distribution channels: Banking, Finance & Investment Industry, Companies ...
• Published on September 13, 2022 - 11:00 GMT

  

  TrippBio Announces Agreement with NIAID to Evaluate PanCytoVir™ Analogs for the Treatment of Viral Diseases

  TrippBio signs a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases to Advance PanCytoVir™ Analogs JACKSONVILLE, FLORIDA, USA, September 13, 2022 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. (TrippBio), a clinical …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on September 8, 2022 - 16:15 GMT

  

  TrippBio Announces Close of Enrollment in the Phase 2 Study of PanCytoVir™ in Patients with Mild-to-Moderate COVID-19

  JACKSONVILLE, FL, USA, September 8, 2022 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. (TrippBio), a clinical development-stage biopharmaceutical company developing antiviral treatments announces that the last patient was enrolled in the Phase 2, dose-range …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on August 2, 2022 - 11:00 GMT

  

  TrippBio and University of Georgia Research Foundation Announce Filing of Additional Patent Application

  Filing expands composition of matter and method of use for PanCytoVir™ and analogs against viruses including SARS-CoV-2, Flu, RSV, Measles, Dengue, and Zika JACKSONVILLE, FLORIDA, UNITED STATES, August 2, 2022 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. ( …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on July 26, 2022 - 11:00 GMT

  

  TrippBio and University of Georgia Research Foundation Expand Licensing Agreement for PanCytoVir™ and Analogs

  The revised agreement broadens TrippBio’s pipeline with new chemical entities that show promise as broadly active anti-viral treatments JACKSONVILLE, FL, USA, July 26, 2022 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. (TrippBio), a clinical development-stage …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on July 19, 2022 - 11:00 GMT

  

  TrippBio Announces Initiation of the Phase 2 Study to Evaluate PanCytoVir™ in Patients with Mild-to-Moderate COVID-19

  First patient screened in study to define the antiviral effect of PanCytoVir™ in patients with mild-to-moderate COVID-19 JACKSONVILLE, FL, UNITED STATES, July 19, 2022 /⁨EINPresswire.com⁩/ -- TrippBio, Inc. (TrippBio), a clinical development-stage …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...